drugset / Trial / NCT07570979
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer.
Timeline
- Start
- 2026-05-25
- Primary completion
- 2030-06-03
- Completion
- 2030-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Subject | Enzalutamide | Other / unclassified | — | Oral |
| Subject | INR731 | Unknown | — | Oral |